Association of Baseline Serum Soluble Tumour Necrosis Factor Receptor Levels with the Response of Rheumatoid Arthritis to Janus Kinase Inhibitor Therapy. [PDF]
Int J RheumatolYoshikawa T +4 more
europepmc +1 more source
Exploring the efficacy of baricitinib in treating alopecia areata after failed Janus kinase inhibitor therapy. [PDF]
JAAD Case RepKatamanin O, Ch'en PY, Song EJ.
europepmc +1 more source
Successful Treatment of Refractory Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis (SAPHO) Syndrome with Baricitinib, a Janus Kinase Inhibitor. [PDF]
Clin Cosmet Investig DermatolYang J, Yuan C, Zhou S, Teng Z, Li M.
europepmc +1 more source
Corrigendum to: Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 Trials. [PDF]
J Crohns Colitiseuropepmc +1 more source
Related searches:
Janus kinase inhibitors: efficacy and safety
Current Opinion in Rheumatology, 2023Purpose of review Janus kinase inhibitors (JAKi) have been available for the treatment of rheumatoid arthritis (RA) since 2012 and are indicated for patients with active disease despite csDMARD therapy. Efficacy and safety, as demonstrated in the clinical trials, was similar to biologics. A recent post marketing trial suggested
Stanley, Cohen, Virginia, Reddy
openaire +2 more sources
Janus kinase inhibitors for alopecia areata
Journal of the American Academy of Dermatology, 2023Janus kinase (JAK) inhibitors have ushered in a new era in alopecia areata (AA). Historically, moderate-to-severe AA was refractory to treatment. JAK inhibitors have changed that; now, treatment of moderate-to-severe AA is possible. Here, we briefly review the history of and rationale for JAK inhibitor treatment of AA, phase 3 clinical trial data, and ...
Brett A, King, Brittany G, Craiglow
openaire +2 more sources
Investigational Janus kinase inhibitors
Expert Opinion on Investigational Drugs, 2013Dysregulation of the Janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway is central to the pathophysiology of myeloproliferative neoplasms (MPN). Small molecule inhibitors of JAK family members are currently under investigation for the treatment of MPN.
Constantine S, Tam, Srdan, Verstovsek
openaire +2 more sources
Oral Janus kinase inhibitors for atopic dermatitis
Annals of Allergy, Asthma & Immunology, 2023Atopic dermatitis (AD) is one of the most common inflammatory skin conditions. The pathogenesis of AD involves skin barrier disruption and immune activation of T-helper (TH)2 and TH22 and varying degrees of TH1 and TH17 activation in various patient subtypes.
Daniela, Mikhaylov +3 more
openaire +2 more sources
Novel Janus-kinase (JAK) Inhibitors in Myelofibrosis
Expert Opinion on Investigational Drugs, 2023JAK inhibitors (JAKis), used in the treatment of myelofibrosis, have entered standard treatment, providing significant improvements in spleen size and symptom burden. Although splenomegaly provides a reduction and some improvement in cytopenia, there is still a way to go. Novel JAKis are being investigated to overcome barriers to treatment access, such
Yildiz Ipek +3 more
openaire +2 more sources